OXBOF (Oxford BioDynamics) Moat Score: 3/10 (As of Jul. 01, 2026)


What is Oxford BioDynamics Moat Score?

Oxford BioDynamics OXBOF -33.33% Moat Score is 3 as of Jul. 01, 2026. The stock has 4 warning signs investors should review. Among 216 Medical Diagnostics & Research companies, Oxford BioDynamics ranks better than 76.85% on this metric.

Oxford BioDynamics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Oxford BioDynamics has No Moat: Oxford BioDynamics has very weak competitive advantages. While it possesses some intellectual property, it lacks market leadership, brand strength, and significant customer switching costs. The company's innovation is not yet impactful enough to establish a durable moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Oxford BioDynamics might have No Moat - Very weak/transient advantages.

Oxford BioDynamics  (OTCPK:OXBOF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Oxford BioDynamics Moat Score Related Terms

OXBOF vs TMO, DHR, IDXX: Moat Score Comparison

For the Diagnostics & Research subindustry, Oxford BioDynamics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oxford BioDynamics Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Oxford BioDynamics's Moat Score distribution charts can be found below:

* The bar in red indicates where Oxford BioDynamics's Moat Score falls into.


Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Oxford BioDynamics (OXBOF) has a Moat Score of 3 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Oxford BioDynamics ranks #50 out of 216 companies in the Medical Diagnostics & Research industry, placing it in the top 23.1%.
Is Oxford BioDynamics' Moat Score too high?
Oxford BioDynamics' current Moat Score is 3. Based on the distribution chart, Oxford BioDynamics ranks #50 out of 216 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Oxford BioDynamics' Moat Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Oxford BioDynamics ranks #50 out of 216 companies for Moat Score. This places Oxford BioDynamics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Oxford BioDynamics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.00 — trading 96.7% below its estimated fair value. The current Moat Score is 3. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Moat Score is 3 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.